February 18, 2022
Paper recently published in The Lancet Oncology demonstrates that sotorasib may be a therapeutic strategy for heavily pretreated patients with KRAS p.G12C mutated metastatic CRC, whose […]
February 18, 2022
In this edition of his monthly column, Tiago Biachi, M.D. Advanced Fellow of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, discusses controversies in first-line treatment […]
February 18, 2022
For decades, despite the poor survival outcomes, the standard treatment for advanced or metastatic esophageal squamous-cell carcinoma was based on chemotherapy (i.e. fluoropyrimidine plus platinum). However, […]
July 7, 2021
Nivolumab demonstrated superior overall survival versus chemotherapy in patients with previously treated esophageal squamous cell carcinoma, according to ATTRACTION-3 data. At ASCO 2021, immunotherapy efficacy data were released in the first–line setting of Checkmate […]
July 6, 2021
Nivolumab is known to demonstrate significant improvement in disease-free survival versus placebo in patients with resected stage II/III esophageal cancer with residual pathologic disease after neoadjuvant chemoradiotherapy, according to a recent publication in NEJM […]
July 2, 2021
Pembrolizumab versus chemotherapy showed progression-free survival improvement in the second provisional analysis in patients with the tumor. The study continued until the final overall survival (OS) analysis, planned after 190 OS events […]
April 26, 2021
Neoadjuvant immunotherapy can induce pathological responses and immunological memory in different malignancies, being a potential therapy for hepatocellular carcinoma A multi-cohort, phase II study (NCT03916627) of neoadjuvant cemiplimab (an anti-PD-1 antibody) for the treatment […]
April 20, 2021
Trastuzumab is a monoclonal antibody directed to HER2, indicated in combination with chemotherapy in 20 to 30% metastatic esophageal or gastric adenocarcinomas that overexpress HER2. However, the […]
April 5, 2021
The team previously demonstrated that circulating hybrid cells (CD45-positive/CK-positive) are found in high numbers in pancreatic adenocarcinoma and are better correlated with overall survival than traditional circulating tumor […]